Quality & complianceOfficial

Denmark flags Aimovig 140 mg supply problems linked to manufacturing issues

🇩🇰 DKMA · Wed 18 Nov 2026

The Danish Medicines Agency reports current supply difficulties with Novartis's erenumab 140 mg pre-filled pen, expected to last from mid-November to early December 2026.

The Danish Medicines Agency (DKMA) has published a supply notice for Aimovig 140 mg solution for injection in pre-filled pen, marketed in Denmark by Novartis Healthcare A/S. The notice is dated 18 November 2026 and states that there are current problems with supply.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.